• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雷公藤多苷片治疗狼疮性肾炎的有效性和安全性:系统评价和 Meta 分析。

Effectiveness and safety of tripterygium glycosides tablet for lupus nephritis: a systematic review and Meta-analysis.

机构信息

Department of Rheumatology, the Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou 510006, China.

Department of Nephrology, Jiangmen Hospital of Chinese Medicine Affiliated to Jinan University, Jiangmen 529000, China.

出版信息

J Tradit Chin Med. 2022 Oct;42(5):671-680. doi: 10.19852/j.cnki.jtcm.2022.05.001.

DOI:10.19852/j.cnki.jtcm.2022.05.001
PMID:36083472
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9924789/
Abstract

OBJECTIVE

To investigate the effectiveness and safety of tripterygium glycosides (TG) tablet for the treatment of Lupus nephritis (LN).

METHODS

Several databases were systematically searched including PubMed, Embase, Cochrane, Wiley, China National Knowledge Infrastructure Database, SinoMed and Wanfang Library till June 20, 2020. Revman5.3 was utilized to analyze the data according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement.

RESULTS

In total, 8 randomized controlled trials involving 583 participants were identified. Meta-analyses showed that, compared with glucocorticoids (GC) alone, the combination with TG tablet provided a statistically significant improvement in total remission (TR) ( = 1.27, 95% : 1.08-1.50, = 0.004), complete remission (CR) ( = 1.61, 95% : 1.05-2.47, = 0.03) and C3 levels ( = 0.27, 95% : 0.14-0.39, < 0.000 1), C4 levels ( = 0.12, 95% : 0.07-0.17, < 0.000 01). No significant differences were seen in TR, CR, proteinuria, serum creatinine, C3 and C4 (TR: = 1.00, 95% : 0.87-1.16, = 0.95; CR: = 1.10, 95% : 0.78-1.56, = 0.58; proteinuria levels: = -0.06, 95% : -0.13 to 0.01, = 0.10; serum creatinine levels: = -0.01, 95%: -7.36 to 7.35, = 1.00; C3 levels: = 0.01, 95%: -0.06 to 0.07, = 0.84; C4 levels: = -0.01, 95%: -0.03 to 0.01, = 0.49) between azathioprine (AZA) / leflomit (LEF) + GC and TG tablet + GC. Adverse events (hepatic dysfunction, nausea, vomitting) showed no statistical differences between the TG tablet + GC group and the GC group. There were more new onset of irregular menstruation in the TG tablet + GC group than those in the AZA + GC ( = 3.57, 95% : 1.40-9.11, = 0.008) /LEF+ GC ( = 6.69, 95% : 2.42-18.46, = 0.000 2) group, but leucopenia lower than those in AZA + GC group ( = 0.38, 95% : 0.17-0.85, = 0.02) and alopecia ( = 0.14, 95% : 0.03-0.77, = 0.02) and rash ( = 0.09, 95% : 0.01-0.69, = 0.02) lower than those in LEF + GC group.

CONCLUSIONS

This review indicates that TG tablet maybe effective in LN treatment. Nevertheless, adverse events cannot be ignored. Large sample, multi-center, high-quality clinical studies are needed to verify the exact effects and safety of TG tablet in treatment of LN.

摘要

目的

探讨雷公藤多苷(TG)片治疗狼疮性肾炎(LN)的有效性和安全性。

方法

系统检索 PubMed、Embase、Cochrane、Wiley、中国知网、中国生物医学文献数据库、万方数据库,检索时间截至 2020 年 6 月 20 日。采用 Revman5.3 软件进行数据分析,并按照系统评价和荟萃分析报告的首选报告项目进行报告。

结果

共纳入 8 项随机对照试验,涉及 583 名参与者。Meta 分析结果显示,与糖皮质激素(GC)单独治疗相比,TG 片联合治疗在总缓解率(TR)( = 1.27,95%:1.08-1.50, = 0.004)、完全缓解率(CR)( = 1.61,95%:1.05-2.47, = 0.03)和 C3 水平( = 0.27,95%:0.14-0.39, < 0.000 1)、C4 水平( = 0.12,95%:0.07-0.17, < 0.000 01)方面有统计学意义的改善。TR、CR、蛋白尿、血肌酐、C3 和 C4 方面未见统计学差异(TR: = 1.00,95%:0.87-1.16, = 0.95;CR: = 1.10,95%:0.78-1.56, = 0.58;蛋白尿水平: = -0.06,95%:-0.13 至 0.01, = 0.10;血肌酐水平: = -0.01,95%:-7.36 至 7.35, = 1.00;C3 水平: = 0.01,95%:-0.06 至 0.07, = 0.84;C4 水平: = -0.01,95%:-0.03 至 0.01, = 0.49)。与 AZA/LEF+GC 联合 TG 片治疗相比,TG 片联合 GC 组与 GC 组之间的不良反应(肝功能障碍、恶心、呕吐)无统计学差异。与 AZA+GC( = 3.57,95%:1.40-9.11, = 0.008)/LEF+GC( = 6.69,95%:2.42-18.46, = 0.000 2)组相比,TG 片联合 GC 组新出现不规则月经的发生率更高,但白细胞减少的发生率低于 AZA+GC 组( = 0.38,95%:0.17-0.85, = 0.02)和脱发( = 0.14,95%:0.03-0.77, = 0.02)和皮疹( = 0.09,95%:0.01-0.69, = 0.02)的发生率低于 LEF+GC 组。

结论

本综述表明,TG 片可能对 LN 治疗有效。然而,不良反应不容忽视。需要更大样本、多中心、高质量的临床研究来验证 TG 片在 LN 治疗中的确切疗效和安全性。

相似文献

1
Effectiveness and safety of tripterygium glycosides tablet for lupus nephritis: a systematic review and Meta-analysis.雷公藤多苷片治疗狼疮性肾炎的有效性和安全性:系统评价和 Meta 分析。
J Tradit Chin Med. 2022 Oct;42(5):671-680. doi: 10.19852/j.cnki.jtcm.2022.05.001.
2
[Tripterygium glycosides in treatment of henoch-schonlein purpura nephritis: a systematic review of randomized controlled trials].雷公藤多苷治疗过敏性紫癜性肾炎:随机对照试验的系统评价
Zhongguo Zhong Yao Za Zhi. 2018 Jul;43(13):2806-2816. doi: 10.19540/j.cnki.cjcmm.20180327.005.
3
[Meta-analysis on safety of Tripterygium Glycosides Tablets in treatment of rheumatoid arthritis].[雷公藤多苷片治疗类风湿关节炎安全性的Meta分析]
Zhongguo Zhong Yao Za Zhi. 2020 Feb;45(4):775-790. doi: 10.19540/j.cnki.cjcmm.20191225.501.
4
Efficacy and Safety of Tripterygium Glycoside in the Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis Based on the Duration of Medication.基于用药时长的雷公藤苷治疗糖尿病肾病的疗效及安全性的系统评价和 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 20;12:656621. doi: 10.3389/fendo.2021.656621. eCollection 2021.
5
The effectiveness and safety of Tripterygium wilfordii glycosides combined with disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 40 randomized controlled trials.雷公藤多苷联合改善病情抗风湿药治疗类风湿关节炎的有效性和安全性:40 项随机对照试验的系统评价和荟萃分析。
Phytother Res. 2021 Jun;35(6):2902-2924. doi: 10.1002/ptr.6996. Epub 2020 Dec 23.
6
Efficacy and safety of tripterygium glycosides for Graves ophthalmopathy: A systematic review and meta-analysis.雷公藤多苷治疗Graves眼病的疗效与安全性:一项系统评价和Meta分析
Medicine (Baltimore). 2019 Dec;98(50):e18242. doi: 10.1097/MD.0000000000018242.
7
[Systematic reviews of effects of Tripterygium Glycosides Tablets on pro-inflammatory factors in rheumatoid arthritis].[雷公藤多苷片对类风湿关节炎促炎因子影响的系统评价]
Zhongguo Zhong Yao Za Zhi. 2020 Feb;45(4):764-774. doi: 10.19540/j.cnki.cjcmm.20191024.401.
8
Efficacy of tripterygium glycosides combined with ARB on diabetic nephropathy: a meta-analysis.雷公藤多苷联合 ARB 治疗糖尿病肾病的疗效:Meta 分析。
Biosci Rep. 2020 Nov 27;40(11). doi: 10.1042/BSR20202391.
9
Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials.雷公藤多苷治疗糖尿病肾病疗效的 Meta 分析: 随机对照试验研究
BMC Nephrol. 2021 Sep 7;22(1):304. doi: 10.1186/s12882-021-02487-8.
10
[Meta-analysis of efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine in treatment of chronic urticarial].雷公藤多苷片联合地氯雷他定治疗慢性荨麻疹的疗效与安全性的Meta分析
Zhongguo Zhong Yao Za Zhi. 2019 Aug;44(16):3551-3557. doi: 10.19540/j.cnki.cjcmm.20181112.001.

引用本文的文献

1
Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials.雷公藤多苷作为免疫调节剂联合传统免疫抑制剂在免疫介导性肾脏疾病中的疗效:一项随机对照试验的系统评价和荟萃分析
Front Pharmacol. 2025 Jul 11;16:1525482. doi: 10.3389/fphar.2025.1525482. eCollection 2025.
2
Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets.自身免疫性疾病:分子发病机制与治疗靶点
MedComm (2020). 2025 Jun 16;6(7):e70262. doi: 10.1002/mco2.70262. eCollection 2025 Jul.
3
Effectiveness and safety of Angong Niuhuang pill in treatment of acute stroke: a systematic review and Meta-analysis.安宫牛黄丸治疗急性脑卒中的有效性和安全性的系统评价和 Meta 分析。
J Tradit Chin Med. 2023 Aug;43(4):650-660. doi: 10.19852/j.cnki.jtcm.20230526.002.
4
Application of herbal traditional Chinese medicine in the treatment of lupus nephritis.中药在狼疮性肾炎治疗中的应用。
Front Pharmacol. 2022 Nov 24;13:981063. doi: 10.3389/fphar.2022.981063. eCollection 2022.

本文引用的文献

1
Triptolide ameliorates lupus via the induction of miR-125a-5p mediating Treg upregulation.雷公藤内酯醇通过诱导 miR-125a-5p 介导 Treg 上调改善狼疮。
Int Immunopharmacol. 2019 Jun;71:14-21. doi: 10.1016/j.intimp.2019.02.047. Epub 2019 Mar 9.
2
Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus.系统性红斑狼疮的流行病学、危险因素和疾病结局的最新进展。
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):188-205. doi: 10.1016/j.berh.2018.09.004. Epub 2018 Sep 27.
3
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.来氟米特与环磷酰胺治疗中国增生型狼疮肾炎患者的诱导缓解:一项随机试验。
Clin Rheumatol. 2019 Mar;38(3):859-867. doi: 10.1007/s10067-018-4348-z. Epub 2018 Nov 13.
4
All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014.1995 年至 2014 年期间,狼疮性肾炎导致的终末期肾病的全因和病因特异性死亡率趋势。
Arthritis Rheumatol. 2019 Mar;71(3):403-410. doi: 10.1002/art.40729. Epub 2019 Jan 9.
5
Induction Therapy for Lupus Nephritis: the Highlights.狼疮性肾炎的诱导治疗:要点。
Curr Rheumatol Rep. 2018 Aug 14;20(10):60. doi: 10.1007/s11926-018-0766-9.
6
The Effectiveness and Safety of Extracts in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.提取物在类风湿性关节炎中的有效性和安全性:一项系统评价与荟萃分析
Front Pharmacol. 2018 Apr 16;9:356. doi: 10.3389/fphar.2018.00356. eCollection 2018.
7
Toxic effects of Tripterygium wilfordii Hook F on the reproductive system of adolescent male rats.雷公藤多苷对青春期雄性大鼠生殖系统的毒性作用。
Biomed Pharmacother. 2017 Nov;95:1338-1345. doi: 10.1016/j.biopha.2017.09.038. Epub 2017 Oct 6.
8
Safety Profiles of Hook F: A Systematic Review and Meta-Analysis.钩F的安全性概况:一项系统评价与荟萃分析
Front Pharmacol. 2016 Nov 8;7:402. doi: 10.3389/fphar.2016.00402. eCollection 2016.
9
Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.昆仙胶囊治疗强直性脊柱炎患者:一项随机安慰剂对照临床试验。
Trials. 2016 Jul 22;17(1):337. doi: 10.1186/s13063-016-1438-6.
10
Human Umbilical Cord Mesenchymal Stem Cells Therapy in Cyclophosphamide-Induced Premature Ovarian Failure Rat Model.人脐带间充质干细胞疗法在环磷酰胺诱导的大鼠卵巢早衰模型中的应用
Biomed Res Int. 2016;2016:2517514. doi: 10.1155/2016/2517514. Epub 2016 Mar 7.